29. Takhzyro

shire
Patients only have to take Shire’s drug once or twice a month, compared with twice a week for Haegarda. (Shire)

Active ingredient: lanadelumab-flyo 
Disease: hereditary angioedema 
Peak sales estimate: $1.8 billion 
Approved: Aug. 23 
Company: Shire 

The scoop: Shire isn’t planning on handing over its leadership position in the hereditary angioedema market any time soon, especially now that Takhzyro has hit the scene. Analysts have said the drug—which has shown it can cut down the incidence of HAE attacks by as much as 87%—could become “best-in-class.”

That’s not to say that its main competition, CSL’s Haegarda, hasn’t also put up stellar efficacy numbers. But patients only have to take Shire’s drug once or twice a month, compared with twice a week for Haegarda. So far, Takhzyro has gotten off to a flying start, raking in $51 million in third-quarter sales after an August approval. That top-line contribution helped Shire’s third-quarter immunology revenues swell to $1.2 billion. — Carly Helfand

29. Takhzyro
Read more on

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.